Stockwatch: Damage Not Controlled
As financial turmoil broke out around the world in the wake of the vote for Brexit, UK pharma majors GlaxoSmithKline and AstraZeneca saw their stock rise. There's an uncertain outlook for the broader life sciences sector.
You may also be interested in...
The Medicines Company, Amarin and Geron have all reported interim analyses for clinical studies recently and investors have been left disappointed. Were we better off without the interim analysis?
The UK biotech’s potential revolutionary approach to allergies has failed to achieve its primary endpoint in a Phase III study, halting much of its research in the allergy area and casting a shadow over UK innovation.
Antisoma is determined to bounce back from the recent catastrophic disappointment with its lead anticancer candidate ASA404 and is hoping clinical data expected over the coming year from other product candidates will turn its fortunes around.